Latest Regulation News

Global Lithium’s proposed acquisition of the Nova Operation from IGO has become unconditional after the ACCC waived its notification requirement. Completion is still pending the shutdown and final shipment timetable, with the transaction not yet completed.

Tuas Limited (ASX:TUA) delivered a sharp FY2026 earnings lift as Simba’s mobile and broadband subscriber base expanded, with statutory profit rising 277% to S$26.0 million. The result arrives with the M1 acquisition abandoned, S$364.5 million raised but not yet allocated, and an unresolved Singapore spectrum investigation.

Eminence Minerals has begun field exploration across three pending licence applications at its Tayra rare earth project in Bahia, Brazil, while continuing a planned 70-hole auger campaign at Campo Grande. The work remains early-stage, with no Mineral Resource defined and Tayra’s tenure still awaiting confirmation from Brazil’s mining regulator.

AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.

Zeus Resources has completed due diligence on its Diaguili copper-gold project in southern Mauritania after regulators validated the environmental notice for exploration. The company will now proceed to the first completion stage of the acquisition, with historical drilling providing the project’s main technical attraction but also its principal qualification.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

OD6 Metals has transformed its portfolio with the completed acquisition of Nevada’s Quinn Fluorspar Project, but the strategic expansion comes alongside a larger loss, ongoing funding needs and substantial permitting risk. The company is now targeting drilling and a maiden resource at Quinn while advancing laboratory-scale rare earth processing work at Splinter Rock.

AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.

Dataworks Group has lodged a prospectus for a non-renounceable entitlement offer targeting A$1.24 million, alongside a committed A$3 million placement. The raising would fund debt repayment, working capital and contract mobilisation, but also materially expand the company’s share count and option pool.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Silver Mines says NSW planning authorities have reaffirmed that the Bowdens Silver Project is in the public interest and approvable subject to strict conditions. The Independent Planning Commission will resume its public hearing in October, with a final decision expected by 9 December 2026.

OD6 Metals has submitted a Plan of Operations covering up to 139 drill pads and bulk sampling at its Quinn Fluorspar Project in Nevada. The application moves the project towards its first systematic drilling campaign, but approval from the U.S. Forest Service remains outstanding.